EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Medicinal Chemistry Perspectives on PFAS in Drug Design: Fluorinated Motifs, Innovation, and Patient Impact

Leena A Otsomaa iD, Michelle R Garnsey iD, Harrie J M Gijsen iD, Peter T W Cheng iD, Scott D Schroeder, Sanjay Menon, Gregory R Ott, Dafydd R Owen

Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 17663-17675

DOI: 10.1021/acs.jmedchem.6c01042 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 28.07.2026. Verfasst von Leena A Otsomaa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Orion Pharma, R&D, Medicine Design, Orion Corporation, Orionintie 1, Espoo02200, Finland. Hauptthemen laut MEDLINE: Drug Design, Fluorocarbons. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: International Consortium for Innovation and Quality in Pharmaceutical Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Concerns about long-chain per- and polyfluoroalkyl substances (PFAS), e.g. PFOS, PFOA, PFNA, have led to broad regulatory initiatives that often treat PFAS as a single class, unintentionally encompassing carbon–fluorine motifs essential to medicinal chemistry. This Perspective examines the implications for small-molecule drug discovery, focusing on −CF2– and −CF3 groups used in active pharmaceutical ingredients. Survey data from medicinal chemistry departments across multiple pharmaceutical organizations highlight the routine use of fluorinated substituents to optimize target engagement, selectivity, permeability, metabolic stability, and systemic exposure, particularly in demanding therapeutic areas. Examples from recently approved drugs and the WHO Model List of Essential Medicines demonstrate how these motifs enable translation of challenging targets into effective therapies. We further discuss the risks of generalized PFAS classifications for pharmaceuticals and emphasize the need for context-specific regulatory approaches that preserve innovation while addressing environmental concerns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignFluorocarbonsHumansChemistry, PharmaceuticalHalogenationDrug DiscoveryAnimals

Stichwörter der Autor:innen

DifluoromethyleneDrug DesignDrug DiscoveryFluorinated MotifsMedicinal ChemistryPatient ImpactRegulatory PolicyTherapeutic InnovationTrifluoromethyl

Substanzen

Fluorocarbons

Autor:innen und Institutionen

  • Orion Pharma, R&D, Medicine Design, Orion Corporation, Orionintie 1, Espoo02200, Finland.
  • Pfizer Research and Development, Cambridge, Massachusetts02139, United States.
  • Global Discovery Chemistry, Therapeutics Discovery (TD), DPDS, Janssen Pharmaceutica NV, Johnson &Johnson Innovative Medicine, BeerseB-2340, Belgium.
  • Oncology Chemistry, Global Discovery Chemistry, Bristol Myers Squibb R & D, P.O. Box 4000, Princeton, New Jersey08540, United States.
  • Medicinal Chemistry, Gilead Sciences, Inc., Foster City, California94404, United States.
  • Department of Medicinal Chemistry, Global Therapeutics, Veterinary Medicine Research and Development, Zoetis, 333 Portage Street, Kalamazoo, Michigan49007, United States.

ORCID-Profile: Leena A Otsomaa, Michelle R Garnsey, Harrie J M Gijsen, Peter T W Cheng

Förderung

  • International Consortium for Innovation and Quality in Pharmaceutical Development

Zitieren

APA

Otsomaa, L. A., Garnsey, M. R., Gijsen, H. J. M., Cheng, P. T. W., Schroeder, S. D., Menon, S., Ott, G. R., & Owen, D. R. (2026). Medicinal Chemistry Perspectives on PFAS in Drug Design: Fluorinated Motifs, Innovation, and Patient Impact. Journal of Medicinal Chemistry, 69(15), 17663-17675. https://doi.org/10.1021/acs.jmedchem.6c01042

Vancouver

Otsomaa LA, Garnsey MR, Gijsen HJM, Cheng PTW, Schroeder SD, Menon S, et al. Medicinal Chemistry Perspectives on PFAS in Drug Design: Fluorinated Motifs, Innovation, and Patient Impact. Journal of Medicinal Chemistry. 2026;69(15):17663-17675. doi:10.1021/acs.jmedchem.6c01042

BibTeX
@article{Otsomaa2026,
  author = {Otsomaa, Leena A and Garnsey, Michelle R and Gijsen, Harrie J M and Cheng, Peter T W and Schroeder, Scott D and Menon, Sanjay and Ott, Gregory R and Owen, Dafydd R},
  title = {Medicinal Chemistry Perspectives on PFAS in Drug Design: Fluorinated Motifs, Innovation, and Patient Impact},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {15},
  pages = {17663--17675},
  doi = {10.1021/acs.jmedchem.6c01042}
}
Kostenlos starten →